

Clare Sun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1676245/publications.pdf>

Version: 2024-02-01

56
papers

1,854
citations

361045

20
h-index

264894

42
g-index

56
all docs

56
docs citations

56
times ranked

2791
citing authors

#	ARTICLE	IF	CITATIONS
1	The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia. <i>Blood Advances</i> , 2023, 7, 145-158.	2.5	15
2	Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare). <i>Clinical Cancer Research</i> , 2022, 28, 603-608.	3.2	11
3	COVID-19 vaccine response in chronic lymphocytic leukaemia is more than just seroconversion. <i>British Journal of Haematology</i> , 2022, , .	1.2	3
4	BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL. <i>Blood Advances</i> , 2022, 6, 1732-1740.	2.5	13
5	Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. <i>Blood</i> , 2021, 137, 185-189.	0.6	110
6	MARCKS affects cell motility and response to BTK inhibitors in CLL. <i>Blood</i> , 2021, 138, 544-556.	0.6	14
7	Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study. <i>Leukemia and Lymphoma</i> , 2021, 62, 1816-1827.	0.6	0
8	Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1828-1839.	0.6	0
9	Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Clinical Cancer Research</i> , 2021, 27, 4624-4633.	3.2	10
10	Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. <i>Leukemia</i> , 2021, 35, 3201-3211.	3.3	25
11	COVID-19 vaccines for patients with haematological conditions. <i>Lancet Haematology</i> , the, 2021, 8, e312-e314.	2.2	18
12	BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL. <i>Blood</i> , 2021, 138, 1843-1854.	0.6	17
13	Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 827-845.	0.9	3
14	Overcoming Acquired Epigenetic Resistance to BTK Inhibitors. <i>Blood Cancer Discovery</i> , 2021, 2, 630-647.	2.6	30
15	Activation of <i>Notch</i> and <i>Myc</i> Signaling via B-cell-Restricted Depletion of <i>Dnmt3a</i> Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2021, 81, 6117-6130.	0.4	10
16	Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL. <i>International Journal of Molecular Sciences</i> , 2020, 21, 68.	1.8	34
17	A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2020, 95, E310-E313.	2.0	3
18	Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib. <i>Clinical Cancer Research</i> , 2020, 26, 2800-2809.	3.2	18

#	ARTICLE	IF	CITATIONS
19	Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2020, 61, 2375-2382.	0.6	16
20	Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 52-54.	0.6	4
21	Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib. <i>Blood</i> , 2020, 136, 93-105.	0.6	68
22	Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 519-522.	0.6	3
23	Polyreactive antibodies in CLL correlate with the level of immunoglobulins not the number of B lymphocytes. <i>Leukemia and Lymphoma</i> , 2019, 60, 242-245.	0.6	4
24	Identifying Major cell Population groups in single-cell RNA-sequencing analysis. <i>GigaScience</i> , 2019, 8, .	3.3	16
25	Protracted course of disseminated adenovirus disease with necrotizing granulomas in the liver. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 180-182.	0.8	2
26	Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I). <i>Blood</i> , 2019, 134, 3053-3053.	0.6	5
27	Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Show Expansion of T-Cell Clonotypes Composed of Antitumor Cytotoxic CD8+ T-Cells. <i>Blood</i> , 2019, 134, 3030-3030.	0.6	0
28	Diverging Clonal Evolution during Sequential Therapy with Chemoimmunotherapy Followed By BTK Inhibitors. <i>Blood</i> , 2019, 134, 850-850.	0.6	1
29	A CD19/CD3 Bispecific Antibody Induces Superior T Cell Responses Against Chronic Lymphocytic Leukemia When Combined with Ibrutinib. <i>Blood</i> , 2019, 134, 2861-2861.	0.6	2
30	Spatial Genomic Heterogeneity in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 3017-3017.	0.6	0
31	Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 3052-3052.	0.6	0
32	Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. <i>Blood</i> , 2018, 131, 2357-2366.	0.6	166
33	Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2792-2800.	0.6	28
34	A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. <i>Blood</i> , 2018, 132, 521-532.	0.6	81
35	Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia. <i>Journal of Immunology</i> , 2018, 201, 1967-1974.	0.4	22
36	Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia. <i>Leukemia</i> , 2017, 31, 340-349.	3.3	33

#	ARTICLE	IF	CITATIONS
37	Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood. <i>Leukemia</i> , 2017, 31, 1340-1347.	3.3	103
38	Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, 874-882.	1.7	67
39	The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. <i>Nature Communications</i> , 2017, 8, 2185.	5.8	148
40	CLL kinetics in the tumor microenvironment. <i>Oncotarget</i> , 2017, 8, 84634-84634.	0.8	2
41	Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib. <i>JAMA Oncology</i> , 2016, 2, 1656.	3.4	75
42	Disruption of <i>in vivo</i> Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib: Findings from an Investigator-Initiated Phase II Study. <i>Clinical Cancer Research</i> , 2016, 22, 1572-1582.	3.2	168
43	Under the microscope: CCL3 and T cells in the microenvironment of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 501-502.	0.6	1
44	The Landscape of Dynamic Genetic Changes in Ibrutinib-Treated CLL. <i>Blood</i> , 2016, 128, 188-188.	0.6	3
45	Dynamic Alterations in Gene Expression in Ibrutinib Treated CLL Reveal Profound Impact on Multiple Signaling Pathways. <i>Blood</i> , 2016, 128, 189-189.	0.6	3
46	Lymphocyte Activation Gene 3-a Novel Therapeutic Target in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 2018-2018.	0.6	1
47	Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. <i>Haematologica</i> , 2015, 100, 1571-1578.	1.7	137
48	Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. <i>Blood</i> , 2015, 126, 2213-2219.	0.6	198
49	Prognosis and Therapy of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. <i>Cancer Treatment and Research</i> , 2015, 165, 147-175.	0.2	11
50	Ibrutinib Inhibits Both B-Cell Receptor and Toll-like Receptor Signaling in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 313-313.	0.6	1
51	Ibrutinib Responsive Micro-RNAs and Upregulation of Tumor Suppressor Targets in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 487-487.	0.6	0
52	p27 ^{kip1} maintains a subset of leukemia stem cells in the quiescent state in murine MLL leukemia. <i>Molecular Oncology</i> , 2013, 7, 1069-1082.	2.1	23
53	Focal Adhesion Kinase Inactivation Reduces the Development of Acute Leukemia and Partially Rescues Hematopoietic Stem Cell Defects in Pten-Knockout Mice. <i>Blood</i> , 2012, 120, 864-864.	0.6	0
54	FLT3 Signaling Enhances Stemness in Murine MLL-AF9 Acute Myeloid Leukemia. <i>Blood</i> , 2012, 120, 2980-2980.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Outcomes of anal fistula surgery in patients with inflammatory bowel disease. American Journal of Surgery, 2010, 199, 609-613.	0.9	46
56	Anal fistula plug and fibrin glue versus conventional treatment in repair of complex anal fistulas. American Journal of Surgery, 2009, 197, 604-608.	0.9	82